Moreover, concerning the impact of IAP inhibition on anticancer drug therapy, we could already show that colorectal cancer (CRC) cells could be sensitized to irinotecan by the Survivin inhibitor LLP3 [59,60] and, most importantly, BV6 also sensitized CRC cells to irinotecan [61]. The gene discussed is BIRC5; the disease is colorectal carcinoma.